UK Panel Warns Against Mass Prostate Cancer Screening
A UK government health panel has decided against recommending widespread prostate cancer screening for most men, sparking "deep disappointment" from several charities and campaigners. The National Screening Committee (NSC) instead advises that only men with a confirmed BRCA1 or BRCA2 faulty gene variant β who are at an increased risk of developing aggressive cancers β should be screened every two years between the ages of 45 and 61.
While some experts welcomed the NSC's evidence-based approach, others expressed concern over the decision to exclude black men, who have a higher risk of late-stage diagnosis. According to the committee, current data on screening black men is "lacking and uncertain," raising fears that targeted screening could lead to high rates of overdiagnosis and overtreatment.
The UK has seen an estimated 55,300 new prostate cancer diagnoses each year, with around 12,200 deaths annually. Despite its prevalence as the second most common male cancer in the country, there is no national screening program due to concerns over the unreliability of PSA tests.
The decision highlights ongoing debates about the benefits and risks of mass screenings, particularly regarding potential harms from overtreatment and overdiagnosis. The NSC estimates that widespread screening could lead to a small reduction in deaths but would result in "a very large number" of men being incorrectly diagnosed with cancer.
Charities like Cancer Research UK have expressed support for the committee's conclusion, stating that current evidence does not show significant benefits from screening for all men or those with family histories of cancer. However, others, including public figures Stephen Fry and Rishi Sunak, are vocal in their opposition to the decision, warning that it will let down vulnerable men who could benefit from early detection.
Health Secretary Wes Streeting has vowed to examine the evidence thoroughly before making a final recommendation in March. While he acknowledged the potential for overdiagnosis and overtreatment, he also emphasized his commitment to improving cancer diagnosis and treatment times within the NHS.
A UK government health panel has decided against recommending widespread prostate cancer screening for most men, sparking "deep disappointment" from several charities and campaigners. The National Screening Committee (NSC) instead advises that only men with a confirmed BRCA1 or BRCA2 faulty gene variant β who are at an increased risk of developing aggressive cancers β should be screened every two years between the ages of 45 and 61.
While some experts welcomed the NSC's evidence-based approach, others expressed concern over the decision to exclude black men, who have a higher risk of late-stage diagnosis. According to the committee, current data on screening black men is "lacking and uncertain," raising fears that targeted screening could lead to high rates of overdiagnosis and overtreatment.
The UK has seen an estimated 55,300 new prostate cancer diagnoses each year, with around 12,200 deaths annually. Despite its prevalence as the second most common male cancer in the country, there is no national screening program due to concerns over the unreliability of PSA tests.
The decision highlights ongoing debates about the benefits and risks of mass screenings, particularly regarding potential harms from overtreatment and overdiagnosis. The NSC estimates that widespread screening could lead to a small reduction in deaths but would result in "a very large number" of men being incorrectly diagnosed with cancer.
Charities like Cancer Research UK have expressed support for the committee's conclusion, stating that current evidence does not show significant benefits from screening for all men or those with family histories of cancer. However, others, including public figures Stephen Fry and Rishi Sunak, are vocal in their opposition to the decision, warning that it will let down vulnerable men who could benefit from early detection.
Health Secretary Wes Streeting has vowed to examine the evidence thoroughly before making a final recommendation in March. While he acknowledged the potential for overdiagnosis and overtreatment, he also emphasized his commitment to improving cancer diagnosis and treatment times within the NHS.